Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 17 entries
Sorted by: Best Match Show Resources per page
Alexander Disease: An Important Mimicker of Focal Brainstem Glioma-Response.

Pediatric blood & cancer

Van Poppel K, Ellison D, Broniscer A, Patay Z, Morris EB.
PMID: 21552504
Pediatr Blood Cancer. 2010 Mar;54(3):487. doi: 10.1002/pbc.22335.

No abstract available.

Cite
Van Poppel K, Ellison D, Broniscer A, et al. Alexander Disease: An Important Mimicker of Focal Brainstem Glioma-Response. Pediatr Blood Cancer. 2010;54(3):487doi: 10.1002/pbc.22335.
Van Poppel, K., Ellison, D., Broniscer, A., Patay, Z., & Morris, E. B. (2010). Alexander Disease: An Important Mimicker of Focal Brainstem Glioma-Response. Pediatric blood & cancer, 54(3), 487. https://doi.org/10.1002/pbc.22335
Van Poppel, Katherine, et al. "Alexander Disease: An Important Mimicker of Focal Brainstem Glioma-Response." Pediatric blood & cancer vol. 54,3 (2010): 487. doi: https://doi.org/10.1002/pbc.22335
Van Poppel K, Ellison D, Broniscer A, Patay Z, Morris EB. Alexander Disease: An Important Mimicker of Focal Brainstem Glioma-Response. Pediatr Blood Cancer. 2010 Mar;54(3):487. doi: 10.1002/pbc.22335. PMID: 21552504; PMCID: PMC3087160.
Copy Download .nbib Format: NLM
Molecular Heterogeneity and Cellular Diversity: Implications for Precision Treatment in Medulloblastoma.

Cancers

Zou H, Poore B, Broniscer A, Pollack IF, Hu B.
PMID: 32164294
Cancers (Basel). 2020 Mar 10;12(3). doi: 10.3390/cancers12030643.

Medulloblastoma, the most common pediatric malignant brain tumor, continues to have a high rate of morbidity and mortality in childhood. Recent advances in cancer genomics, single-cell sequencing, and sophisticated tumor models have revolutionized the characterization and stratification of medulloblastoma....

Cite
Zou H, Poore B, Broniscer A, et al. Molecular Heterogeneity and Cellular Diversity: Implications for Precision Treatment in Medulloblastoma. Cancers (Basel). 2020;12(3)doi: 10.3390/cancers12030643.
Zou, H., Poore, B., Broniscer, A., Pollack, I. F., & Hu, B. (2020). Molecular Heterogeneity and Cellular Diversity: Implications for Precision Treatment in Medulloblastoma. Cancers, 12(3), . https://doi.org/10.3390/cancers12030643
Zou, Han, et al. "Molecular Heterogeneity and Cellular Diversity: Implications for Precision Treatment in Medulloblastoma." Cancers vol. 12,3 (2020). doi: https://doi.org/10.3390/cancers12030643
Zou H, Poore B, Broniscer A, Pollack IF, Hu B. Molecular Heterogeneity and Cellular Diversity: Implications for Precision Treatment in Medulloblastoma. Cancers (Basel). 2020 Mar 10;12(3). doi: 10.3390/cancers12030643. PMID: 32164294; PMCID: PMC7139663.
Copy Download .nbib Format: NLM
Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials.

Clinical cancer research : an official journal of the American Association for Cancer Research

Upadhyaya SA, Robinson GW, Onar-Thomas A, Orr BA, Johann P, Wu G, Billups CA, Tatevossian RG, Dhanda SK, Srinivasan A, Broniscer A, Qaddoumi I, Vinitsky A, Armstrong GT, Bendel AE, Hassall T, Partap S, Fisher PG, Crawford JR, Chintagumpala M, Bouffet E, Gururangan S, Mostafavi R, Sanders RP, Klimo P, Patay Z, Indelicato DJ, Nichols KE, Boop FA, Merchant TE, Kool M, Ellison DW, Gajjar A.
PMID: 33737307
Clin Cancer Res. 2021 May 15;27(10):2879-2889. doi: 10.1158/1078-0432.CCR-20-4731. Epub 2021 Mar 18.

PURPOSE: Report relevance of molecular groups to clinicopathologic features, germline MATERIALS AND METHODS: Seventy-four participants with newly diagnosed ATRT were treated in two trials: infants (SJYC07: age < 3 years; RESULTS: Twenty-four participants (32%) were alive at time of...

Cite
Upadhyaya SA, Robinson GW, Onar-Thomas A, et al. Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials. Clin Cancer Res. 2021;27(10):2879-2889doi: 10.1158/1078-0432.CCR-20-4731.
Upadhyaya, S. A., Robinson, G. W., Onar-Thomas, A., Orr, B. A., Johann, P., Wu, G., Billups, C. A., Tatevossian, R. G., Dhanda, S. K., Srinivasan, A., Broniscer, A., Qaddoumi, I., Vinitsky, A., Armstrong, G. T., Bendel, A. E., Hassall, T., Partap, S., Fisher, P. G., Crawford, J. R., Chintagumpala, M., Bouffet, E., Gururangan, S., Mostafavi, R., Sanders, R. P., Klimo, P., Patay, Z., Indelicato, D. J., Nichols, K. E., Boop, F. A., Merchant, T. E., Kool, M., Ellison, D. W., & Gajjar, A. (2021). Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(10), 2879-2889. https://doi.org/10.1158/1078-0432.CCR-20-4731
Upadhyaya, Santhosh A, et al. "Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,10 (2021): 2879-2889. doi: https://doi.org/10.1158/1078-0432.CCR-20-4731
Upadhyaya SA, Robinson GW, Onar-Thomas A, Orr BA, Johann P, Wu G, Billups CA, Tatevossian RG, Dhanda SK, Srinivasan A, Broniscer A, Qaddoumi I, Vinitsky A, Armstrong GT, Bendel AE, Hassall T, Partap S, Fisher PG, Crawford JR, Chintagumpala M, Bouffet E, Gururangan S, Mostafavi R, Sanders RP, Klimo P, Patay Z, Indelicato DJ, Nichols KE, Boop FA, Merchant TE, Kool M, Ellison DW, Gajjar A. Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials. Clin Cancer Res. 2021 May 15;27(10):2879-2889. doi: 10.1158/1078-0432.CCR-20-4731. Epub 2021 Mar 18. PMID: 33737307; PMCID: PMC8127412.
Copy Download .nbib Format: NLM
Correction to: H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo.

Acta neuropathologica

Silveira AB, Kasper LH, Fan Y, Jin H, Wu G, Shaw TI, Zhu X, Larson JD, Easton J, Shao Y, Yergeau DA, Rosencrance C, Boggs K, Rusch MC, Ding L, Zhang J, Finkelstein D, Noyes RM, Russell BL, Xu B, Broniscer A, Wetmore C, Pounds SB, Ellison DW, Zhang J, Baker SJ.
PMID: 30976974
Acta Neuropathol. 2019 Jun;137(6):1021. doi: 10.1007/s00401-019-02006-y. Epub 2019 Apr 11.

The original article can be found online.

Cite
Silveira AB, Kasper LH, Fan Y, et al. Correction to: H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo. Acta Neuropathol. 2019;137(6):1021doi: 10.1007/s00401-019-02006-y.
Silveira, A. B., Kasper, L. H., Fan, Y., Jin, H., Wu, G., Shaw, T. I., Zhu, X., Larson, J. D., Easton, J., Shao, Y., Yergeau, D. A., Rosencrance, C., Boggs, K., Rusch, M. C., Ding, L., Zhang, J., Finkelstein, D., Noyes, R. M., Russell, B. L., Xu, B., Broniscer, A., Wetmore, C., Pounds, S. B., Ellison, D. W., Zhang, J., & Baker, S. J. (2019). Correction to: H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo. Acta neuropathologica, 137(6), 1021. https://doi.org/10.1007/s00401-019-02006-y
Silveira, André B, et al. "Correction to: H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo." Acta neuropathologica vol. 137,6 (2019): 1021. doi: https://doi.org/10.1007/s00401-019-02006-y
Silveira AB, Kasper LH, Fan Y, Jin H, Wu G, Shaw TI, Zhu X, Larson JD, Easton J, Shao Y, Yergeau DA, Rosencrance C, Boggs K, Rusch MC, Ding L, Zhang J, Finkelstein D, Noyes RM, Russell BL, Xu B, Broniscer A, Wetmore C, Pounds SB, Ellison DW, Zhang J, Baker SJ. Correction to: H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo. Acta Neuropathol. 2019 Jun;137(6):1021. doi: 10.1007/s00401-019-02006-y. Epub 2019 Apr 11. PMID: 30976974; PMCID: PMC6999025.
Copy Download .nbib Format: NLM
[.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Bag AK, Wing MN, Sabin ND, Hwang SN, Armstrong GT, Han Y, Li Y, Snyder S, Robinson GW, Qaddoumi I, Broniscer A, Lucas JT, Shulkin BL.
PMID: 34446453
J Nucl Med. 2021 Aug 26; doi: 10.2967/jnumed.120.261891. Epub 2021 Aug 26.

No abstract available.

Cite
Bag AK, Wing MN, Sabin ND, et al. [. J Nucl Med. 2021;doi: 10.2967/jnumed.120.261891.
Bag, A. K., Wing, M. N., Sabin, N. D., Hwang, S. N., Armstrong, G. T., Han, Y., Li, Y., Snyder, S., Robinson, G. W., Qaddoumi, I., Broniscer, A., Lucas, J. T., & Shulkin, B. L. (2021). [. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, . https://doi.org/10.2967/jnumed.120.261891
Bag, Asim K, et al. "[." Journal of nuclear medicine : official publication, Society of Nuclear Medicine vol. (2021). doi: https://doi.org/10.2967/jnumed.120.261891
Bag AK, Wing MN, Sabin ND, Hwang SN, Armstrong GT, Han Y, Li Y, Snyder S, Robinson GW, Qaddoumi I, Broniscer A, Lucas JT, Shulkin BL. [. J Nucl Med. 2021 Aug 26; doi: 10.2967/jnumed.120.261891. Epub 2021 Aug 26. PMID: 34446453.
Copy Download .nbib Format: NLM
Correction to: Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors.

Cancer chemotherapy and pharmacology

Reddick SJ, Campagne O, Huang J, Onar-Thomas A, Broniscer A, Gajjar A, Stewart CF.
PMID: 31912224
Cancer Chemother Pharmacol. 2020 Feb;85(2):475. doi: 10.1007/s00280-019-04026-7.

In the original publication of the article, the authors wish to note an error in the section "Funding".

Cite
Reddick SJ, Campagne O, Huang J, et al. Correction to: Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors. Cancer Chemother Pharmacol. 2020;85(2):475doi: 10.1007/s00280-019-04026-7.
Reddick, S. J., Campagne, O., Huang, J., Onar-Thomas, A., Broniscer, A., Gajjar, A., & Stewart, C. F. (2020). Correction to: Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors. Cancer chemotherapy and pharmacology, 85(2), 475. https://doi.org/10.1007/s00280-019-04026-7
Reddick, Samuel J, et al. "Correction to: Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors." Cancer chemotherapy and pharmacology vol. 85,2 (2020): 475. doi: https://doi.org/10.1007/s00280-019-04026-7
Reddick SJ, Campagne O, Huang J, Onar-Thomas A, Broniscer A, Gajjar A, Stewart CF. Correction to: Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors. Cancer Chemother Pharmacol. 2020 Feb;85(2):475. doi: 10.1007/s00280-019-04026-7. PMID: 31912224.
Copy Download .nbib Format: NLM
Phase I study using crenolanib to target PDGFR kinase in children and young adults with newly diagnosed DIPG or recurrent high-grade glioma, including DIPG.

Neuro-oncology advances

Tinkle CL, Broniscer A, Chiang J, Campagne O, Huang J, Orr BA, Li X, Patay Z, Zhang J, Baker SJ, Merchant TE, Jain V, Onar-Thomas A, Stewart CF, Wetmore C, Gajjar A.
PMID: 34993482
Neurooncol Adv. 2021 Dec 01;3(1):vdab179. doi: 10.1093/noajnl/vdab179. eCollection 2021.

BACKGROUND: Platelet-derived growth factor receptor (PDGFR) signaling has been directly implicated in pediatric high-grade gliomagenesis. This study evaluated the safety and tolerability of crenolanib, a potent, selective inhibitor of PDGFR-mediated phosphorylation, in pediatric patients with high-grade glioma (HGG).METHODS: We...

Cite
Tinkle CL, Broniscer A, Chiang J, et al. Phase I study using crenolanib to target PDGFR kinase in children and young adults with newly diagnosed DIPG or recurrent high-grade glioma, including DIPG. Neurooncol Adv. 2021;3(1):vdab179doi: 10.1093/noajnl/vdab179.
Tinkle, C. L., Broniscer, A., Chiang, J., Campagne, O., Huang, J., Orr, B. A., Li, X., Patay, Z., Zhang, J., Baker, S. J., Merchant, T. E., Jain, V., Onar-Thomas, A., Stewart, C. F., Wetmore, C., & Gajjar, A. (2021). Phase I study using crenolanib to target PDGFR kinase in children and young adults with newly diagnosed DIPG or recurrent high-grade glioma, including DIPG. Neuro-oncology advances, 3(1), vdab179. https://doi.org/10.1093/noajnl/vdab179
Tinkle, Christopher L, et al. "Phase I study using crenolanib to target PDGFR kinase in children and young adults with newly diagnosed DIPG or recurrent high-grade glioma, including DIPG." Neuro-oncology advances vol. 3,1 (2021): vdab179. doi: https://doi.org/10.1093/noajnl/vdab179
Tinkle CL, Broniscer A, Chiang J, Campagne O, Huang J, Orr BA, Li X, Patay Z, Zhang J, Baker SJ, Merchant TE, Jain V, Onar-Thomas A, Stewart CF, Wetmore C, Gajjar A. Phase I study using crenolanib to target PDGFR kinase in children and young adults with newly diagnosed DIPG or recurrent high-grade glioma, including DIPG. Neurooncol Adv. 2021 Dec 01;3(1):vdab179. doi: 10.1093/noajnl/vdab179. eCollection 2021. PMID: 34993482; PMCID: PMC8717895.
Copy Download .nbib Format: NLM
Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials.

Clinical cancer research : an official journal of the American Association for Cancer Research

Upadhyaya SA, Robinson GW, Onar-Thomas A, Orr BA, Johann P, Wu G, Billups CA, Tatevossian RG, Dhanda SK, Srinivasan A, Broniscer A, Qaddoumi I, Vinitsky A, Armstrong GT, Bendel AE, Hassall T, Partap S, Fisher PG, Crawford JR, Chintagumpala M, Bouffet E, Gururangan S, Mostafavi R, Sanders RP, Klimo P, Patay Z, Indelicato DJ, Nichols KE, Boop FA, Merchant TE, Kool M, Ellison DW, Gajjar A.
PMID: 33737307
Clin Cancer Res. 2021 May 15;27(10):2879-2889. doi: 10.1158/1078-0432.CCR-20-4731. Epub 2021 Mar 18.

PURPOSE: Report relevance of molecular groups to clinicopathologic features, germline MATERIALS AND METHODS: Seventy-four participants with newly diagnosed ATRT were treated in two trials: infants (SJYC07: age < 3 years; RESULTS: Twenty-four participants (32%) were alive at time of...

Cite
Upadhyaya SA, Robinson GW, Onar-Thomas A, et al. Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials. Clin Cancer Res. 2021;27(10):2879-2889doi: 10.1158/1078-0432.CCR-20-4731.
Upadhyaya, S. A., Robinson, G. W., Onar-Thomas, A., Orr, B. A., Johann, P., Wu, G., Billups, C. A., Tatevossian, R. G., Dhanda, S. K., Srinivasan, A., Broniscer, A., Qaddoumi, I., Vinitsky, A., Armstrong, G. T., Bendel, A. E., Hassall, T., Partap, S., Fisher, P. G., Crawford, J. R., Chintagumpala, M., Bouffet, E., Gururangan, S., Mostafavi, R., Sanders, R. P., Klimo, P., Patay, Z., Indelicato, D. J., Nichols, K. E., Boop, F. A., Merchant, T. E., Kool, M., Ellison, D. W., & Gajjar, A. (2021). Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(10), 2879-2889. https://doi.org/10.1158/1078-0432.CCR-20-4731
Upadhyaya, Santhosh A, et al. "Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,10 (2021): 2879-2889. doi: https://doi.org/10.1158/1078-0432.CCR-20-4731
Upadhyaya SA, Robinson GW, Onar-Thomas A, Orr BA, Johann P, Wu G, Billups CA, Tatevossian RG, Dhanda SK, Srinivasan A, Broniscer A, Qaddoumi I, Vinitsky A, Armstrong GT, Bendel AE, Hassall T, Partap S, Fisher PG, Crawford JR, Chintagumpala M, Bouffet E, Gururangan S, Mostafavi R, Sanders RP, Klimo P, Patay Z, Indelicato DJ, Nichols KE, Boop FA, Merchant TE, Kool M, Ellison DW, Gajjar A. Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials. Clin Cancer Res. 2021 May 15;27(10):2879-2889. doi: 10.1158/1078-0432.CCR-20-4731. Epub 2021 Mar 18. PMID: 33737307; PMCID: PMC8127412.
Copy Download .nbib Format: NLM
Corrigendum: Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss.

Nature genetics

Xu H, Robinson GW, Huang J, Lim JY, Zhang H, Bass JK, Broniscer A, Chintagumpala M, Bartels U, Gururangan S, Hassall T, Fisher M, Cohn R, Yamashita T, Teitz T, Zuo J, Onar-Thomas A, Gajjar A, Stewart CF, Yang JJ.
PMID: 25814313
Nat Genet. 2015 Apr;47(4):423. doi: 10.1038/ng0415-423.

No abstract available.

Cite
Xu H, Robinson GW, Huang J, et al. Corrigendum: Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss. Nat Genet. 2015;47(4):423doi: 10.1038/ng0415-423.
Xu, H., Robinson, G. W., Huang, J., Lim, J. Y., Zhang, H., Bass, J. K., Broniscer, A., Chintagumpala, M., Bartels, U., Gururangan, S., Hassall, T., Fisher, M., Cohn, R., Yamashita, T., Teitz, T., Zuo, J., Onar-Thomas, A., Gajjar, A., Stewart, C. F., & Yang, J. J. (2015). Corrigendum: Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss. Nature genetics, 47(4), 423. https://doi.org/10.1038/ng0415-423
Xu, Heng, et al. "Corrigendum: Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss." Nature genetics vol. 47,4 (2015): 423. doi: https://doi.org/10.1038/ng0415-423
Xu H, Robinson GW, Huang J, Lim JY, Zhang H, Bass JK, Broniscer A, Chintagumpala M, Bartels U, Gururangan S, Hassall T, Fisher M, Cohn R, Yamashita T, Teitz T, Zuo J, Onar-Thomas A, Gajjar A, Stewart CF, Yang JJ. Corrigendum: Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss. Nat Genet. 2015 Apr;47(4):423. doi: 10.1038/ng0415-423. PMID: 25814313.
Copy Download .nbib Format: NLM
The spectrum of rare central nervous system (CNS) tumors with EWSR1-non-ETS fusions: experience from three pediatric institutions with review of the literature.

Brain pathology (Zurich, Switzerland)

Lopez-Nunez O, Cafferata B, Santi M, Ranganathan S, Pearce TM, Kulich SM, Bailey KM, Broniscer A, Rossi S, Zin A, Nasrallah MP, Li MM, Zhong Y, Miele E, Alaggio R, Surrey LF.
PMID: 32997853
Brain Pathol. 2021 Jan;31(1):70-83. doi: 10.1111/bpa.12900. Epub 2020 Nov 06.

The group of CNS mesenchymal (non-meningothelial) and primary glial/neuronal tumors in association with EWSR1-non-ETS rearrangements comprises a growing spectrum of entities, mostly reported in isolation with incomplete molecular profiling. Archival files from three pediatric institutions were queried for unusual...

Cite
Lopez-Nunez O, Cafferata B, Santi M, et al. The spectrum of rare central nervous system (CNS) tumors with EWSR1-non-ETS fusions: experience from three pediatric institutions with review of the literature. Brain Pathol. 2020;31(1):70-83doi: 10.1111/bpa.12900.
Lopez-Nunez, O., Cafferata, B., Santi, M., Ranganathan, S., Pearce, T. M., Kulich, S. M., Bailey, K. M., Broniscer, A., Rossi, S., Zin, A., Nasrallah, M. P., Li, M. M., Zhong, Y., Miele, E., Alaggio, R., & Surrey, L. F. (2021). The spectrum of rare central nervous system (CNS) tumors with EWSR1-non-ETS fusions: experience from three pediatric institutions with review of the literature. Brain pathology (Zurich, Switzerland), 31(1), 70-83. https://doi.org/10.1111/bpa.12900
Lopez-Nunez, Oscar, et al. "The spectrum of rare central nervous system (CNS) tumors with EWSR1-non-ETS fusions: experience from three pediatric institutions with review of the literature." Brain pathology (Zurich, Switzerland) vol. 31,1 (2021): 70-83. doi: https://doi.org/10.1111/bpa.12900
Lopez-Nunez O, Cafferata B, Santi M, Ranganathan S, Pearce TM, Kulich SM, Bailey KM, Broniscer A, Rossi S, Zin A, Nasrallah MP, Li MM, Zhong Y, Miele E, Alaggio R, Surrey LF. The spectrum of rare central nervous system (CNS) tumors with EWSR1-non-ETS fusions: experience from three pediatric institutions with review of the literature. Brain Pathol. 2021 Jan;31(1):70-83. doi: 10.1111/bpa.12900. Epub 2020 Nov 06. PMID: 32997853; PMCID: PMC8018079.
Copy Download .nbib Format: NLM
Characteristics of patients ≥10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry.

Neuro-oncology

Erker C, Lane A, Chaney B, Leary S, Minturn JE, Bartels U, Packer RJ, Dorris K, Gottardo NG, Warren KE, Broniscer A, Kieran MW, Zhu X, White P, Dexheimer PJ, Black K, Asher A, DeWire M, Hansford JR, Gururangan S, Nazarian J, Ziegler DS, Sandler E, Bartlett A, Goldman S, Shih CS, Hassall T, Dholaria H, Bandopadhayay P, Samson Y, Monje M, Fisher PG, Dodgshun A, Parkin S, Chintagumpala M, Tsui K, Gass D, Larouche V, Broxson E, Garcia Lombardi M, Wang SS, Ma J, Hawkins C, Hamideh D, Wagner L, Koschmann C, Fuller C, Drissi R, Jones BV, Leach J, Fouladi M.
PMID: 34114629
Neuro Oncol. 2022 Jan 05;24(1):141-152. doi: 10.1093/neuonc/noab140.

BACKGROUND: Diffuse intrinsic pontine gliomas (DIPG) generally occur in young school-age children, although can occur in adolescents and young adults. The purpose of this study was to describe clinical, radiological, pathologic, and molecular characteristics in patients ≥10 years of...

Cite
Erker C, Lane A, Chaney B, et al. Characteristics of patients ≥10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry. Neuro Oncol. 2022;24(1):141-152doi: 10.1093/neuonc/noab140.
Erker, C., Lane, A., Chaney, B., Leary, S., Minturn, J. E., Bartels, U., Packer, R. J., Dorris, K., Gottardo, N. G., Warren, K. E., Broniscer, A., Kieran, M. W., Zhu, X., White, P., Dexheimer, P. J., Black, K., Asher, A., DeWire, M., Hansford, J. R., Gururangan, S., Nazarian, J., Ziegler, D. S., Sandler, E., Bartlett, A., Goldman, S., Shih, C. S., Hassall, T., Dholaria, H., Bandopadhayay, P., Samson, Y., Monje, M., Fisher, P. G., Dodgshun, A., Parkin, S., Chintagumpala, M., Tsui, K., Gass, D., Larouche, V., Broxson, E., Garcia Lombardi, M., Wang, S. S., Ma, J., Hawkins, C., Hamideh, D., Wagner, L., Koschmann, C., Fuller, C., Drissi, R., Jones, B. V., Leach, J., & Fouladi, M. (2022). Characteristics of patients ≥10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry. Neuro-oncology, 24(1), 141-152. https://doi.org/10.1093/neuonc/noab140
Erker, Craig, et al. "Characteristics of patients ≥10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry." Neuro-oncology vol. 24,1 (2022): 141-152. doi: https://doi.org/10.1093/neuonc/noab140
Erker C, Lane A, Chaney B, Leary S, Minturn JE, Bartels U, Packer RJ, Dorris K, Gottardo NG, Warren KE, Broniscer A, Kieran MW, Zhu X, White P, Dexheimer PJ, Black K, Asher A, DeWire M, Hansford JR, Gururangan S, Nazarian J, Ziegler DS, Sandler E, Bartlett A, Goldman S, Shih CS, Hassall T, Dholaria H, Bandopadhayay P, Samson Y, Monje M, Fisher PG, Dodgshun A, Parkin S, Chintagumpala M, Tsui K, Gass D, Larouche V, Broxson E, Garcia Lombardi M, Wang SS, Ma J, Hawkins C, Hamideh D, Wagner L, Koschmann C, Fuller C, Drissi R, Jones BV, Leach J, Fouladi M. Characteristics of patients ≥10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry. Neuro Oncol. 2022 Jan 05;24(1):141-152. doi: 10.1093/neuonc/noab140. PMID: 34114629.
Copy Download .nbib Format: NLM
Characteristics of patients ≥10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry.

Neuro-oncology

Erker C, Lane A, Chaney B, Leary S, Minturn JE, Bartels U, Packer RJ, Dorris K, Gottardo NG, Warren KE, Broniscer A, Kieran MW, Zhu X, White P, Dexheimer PJ, Black K, Asher A, DeWire M, Hansford JR, Gururangan S, Nazarian J, Ziegler DS, Sandler E, Bartlett A, Goldman S, Shih CS, Hassall T, Dholaria H, Bandopadhayay P, Samson Y, Monje M, Fisher PG, Dodgshun A, Parkin S, Chintagumpala M, Tsui K, Gass D, Larouche V, Broxson E, Garcia Lombardi M, Wang SS, Ma J, Hawkins C, Hamideh D, Wagner L, Koschmann C, Fuller C, Drissi R, Jones BV, Leach J, Fouladi M.
PMID: 34114629
Neuro Oncol. 2022 Jan 05;24(1):141-152. doi: 10.1093/neuonc/noab140.

BACKGROUND: Diffuse intrinsic pontine gliomas (DIPG) generally occur in young school-age children, although can occur in adolescents and young adults. The purpose of this study was to describe clinical, radiological, pathologic, and molecular characteristics in patients ≥10 years of...

Cite
Erker C, Lane A, Chaney B, et al. Characteristics of patients ≥10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry. Neuro Oncol. 2022;24(1):141-152doi: 10.1093/neuonc/noab140.
Erker, C., Lane, A., Chaney, B., Leary, S., Minturn, J. E., Bartels, U., Packer, R. J., Dorris, K., Gottardo, N. G., Warren, K. E., Broniscer, A., Kieran, M. W., Zhu, X., White, P., Dexheimer, P. J., Black, K., Asher, A., DeWire, M., Hansford, J. R., Gururangan, S., Nazarian, J., Ziegler, D. S., Sandler, E., Bartlett, A., Goldman, S., Shih, C. S., Hassall, T., Dholaria, H., Bandopadhayay, P., Samson, Y., Monje, M., Fisher, P. G., Dodgshun, A., Parkin, S., Chintagumpala, M., Tsui, K., Gass, D., Larouche, V., Broxson, E., Garcia Lombardi, M., Wang, S. S., Ma, J., Hawkins, C., Hamideh, D., Wagner, L., Koschmann, C., Fuller, C., Drissi, R., Jones, B. V., Leach, J., & Fouladi, M. (2022). Characteristics of patients ≥10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry. Neuro-oncology, 24(1), 141-152. https://doi.org/10.1093/neuonc/noab140
Erker, Craig, et al. "Characteristics of patients ≥10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry." Neuro-oncology vol. 24,1 (2022): 141-152. doi: https://doi.org/10.1093/neuonc/noab140
Erker C, Lane A, Chaney B, Leary S, Minturn JE, Bartels U, Packer RJ, Dorris K, Gottardo NG, Warren KE, Broniscer A, Kieran MW, Zhu X, White P, Dexheimer PJ, Black K, Asher A, DeWire M, Hansford JR, Gururangan S, Nazarian J, Ziegler DS, Sandler E, Bartlett A, Goldman S, Shih CS, Hassall T, Dholaria H, Bandopadhayay P, Samson Y, Monje M, Fisher PG, Dodgshun A, Parkin S, Chintagumpala M, Tsui K, Gass D, Larouche V, Broxson E, Garcia Lombardi M, Wang SS, Ma J, Hawkins C, Hamideh D, Wagner L, Koschmann C, Fuller C, Drissi R, Jones BV, Leach J, Fouladi M. Characteristics of patients ≥10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry. Neuro Oncol. 2022 Jan 05;24(1):141-152. doi: 10.1093/neuonc/noab140. PMID: 34114629; PMCID: PMC8730773.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 17 entries